Dengue Fever (Infectious Disease) – Drugs in Development, 2021
- Pages: 203
- Published: December 2021
- Report Code: GMDHC13191IDB
Global Markets Direct’s, ‘Dengue Fever – Drugs In Development, 2021’, provides an overview of the Dengue Fever pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Dengue Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
– The report provides a snapshot of the global therapeutic landscape of Dengue Fever
– The report reviews pipeline therapeutics for Dengue Fever Hypogonadism by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Dengue Fever Hypogonadism therapeutics and enlists all their major and minor projects
– The report assesses Dengue Fever Hypogonadism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Dengue Fever
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Dengue Fever
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dengue Fever pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
60 Degrees Pharmaceuticals LLC
Abhelix LLC
Abivax SA
AbViro LLC
Atea Pharmaceuticals Inc
Avida Biotech SL
Biological Mimetics Inc
BioNet-Asia Co Ltd
Biotron Ltd
Cadila Healthcare Ltd
Cidara Therapeutics Inc
Codagenix Inc
CycloLab Cyclodextrin Research and Development Laboratory Ltd
Emergex Vaccines Holding Ltd
Ennaid Therapeutics LLC
Etna Biotech Srl
Excivion Ltd
Exopharm Ltd
Globavir Biosciences Inc
Greffex Inc
Hercules Pharmaceuticals BV
HSRx Group
ImmuneMed Inc
Immunotope Inc
Imutex Ltd
Indian Immunologicals Ltd
Inovio Pharmaceuticals Inc
Integral Molecular Inc
Island Pharmaceuticals
Johnson & Johnson
KinoPharma Inc
KM Biologics Co Ltd
Macrophage Therapeutics Inc
Medigen Inc
Moleculin Biotech Inc
Najit Technologies Inc
Novartis AG
Orgenesis Inc
Panacea Biotec Ltd
Plex Pharmaceuticals Inc
ProtInhi BV
Riboscience LLC
Seagull BioSolutions Pvt Ltd
Serum Institute of India Pvt Ltd
Shionogi & Co Ltd
Sun Pharma Advanced Research Company Ltd
Takeda Pharmaceutical Co Ltd
TechnoVax Inc
Theravectys SA
Vir Biotechnology Inc
Virocovax
Visterra Inc
VLP Therapeutics LLC
Xenothera SAS
Zucero Therapeutics Ltd
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.